Atlas FDA

RESTYLANE, RESTYLANE-L,PERLANE,PERLANE-L,RESTYLANE SILK

FDA premarket approval P040024/S073 · decided 2015-07-01

Approval details

PMA number
P040024
Supplement
S073
Supplement type
Panel Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
RESTYLANE, RESTYLANE-L,PERLANE,PERLANE-L,RESTYLANE SILK
Generic name
Implant, dermal, for aesthetic use
Applicant
Q-Med AB
Date received
2014-05-01
Decision date
2015-07-01
Days to decision
426 days
Decision code
APPR
Product code
LMH
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Uppsala
Statement
APPROVAL FOR RESTYLANE LYFT WITH LIDOCAINE. THIS DEVICE IS INDICATED FOR IMPLANTATION INTO THE DEEP DERMIS TO SUPERFICIAL SUBCUTIS FOR THE CORRECTION OF MODERATE TO SEVERE FACIAL FOLDS AND WRINKLES, SUCH AS NASOLABIAL FOLDS; AND FOR SUBCUTANEOUS TO SUPRAPERIOSTEAL IMPLANTATION FOR CHEEK AUGMENTATION AND CORRECTION OF AGE-RELATED MIDFACE CONTOUR DEFICIENCIES IN PATIENTS OVER THE AGE OF 21.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.